Irvine3 Labs, Department of Medical and Oral Sciences and Biotechnologies, Chieti-Pescara University, Pescara, Italy.
International Agency for Pharma-Standard Supplements (IA-PSS), Pescara, Italy.
Minerva Cardioangiol. 2020 Jun;68(3):203-208. doi: 10.23736/S0026-4725.19.05028-X.
The aim of this open registry study was to evaluate the effects of Robuvit® in subjects with hangover after acute alcohol consumption also measuring changes in levels of oxidative stress. A group using standard management (SM) and a group using SM and Robuvit® 300 mg/day for 3 days were compared.
Nineteen male subjects with hangover were included in the SM group and 22 in the Robuvit® + SM group.
The groups were comparable at baseline. No side effects were observed. Fatigue scores - as the main observable symptom in these subjects, in both groups - were significantly lower in the group using Robuvit® (P<0.05) than in the control group after 24 hours. The scores of other symptoms like weakness, thirst, headache, muscle aches and body pain were significantly lower at 24 hours (P<0.05) with the supplement than in the control group. The scores of residual gastrointestinal symptoms (nausea, vomiting and stomach pain) were also significantly lower at 24 hours with Robuvit® (P<0.05). Sleep and rest were significantly better with Robuvit® (P<0.05). Sensory symptoms and cognitive functions were also significantly better with supplementation in comparison with SM only (P<0.05). Finally, scores of mood, concentration, depression, anxiety, irritability were significantly lower (P<0.05) with Robuvit® though these symptoms need a more specific and complete evaluation. Signs of sympathetic activity, tremor, sweating, increased heart rate improved significantly better with the supplement at 24 hours (P<0.05). Oxidative stress was increased at inclusion in all subjects; in the Robuvit® group, oxidative stress decreased significantly (P<0.05) at 24 hours; in controls (SM) oxidative stress showed minimal changes at 24 hours and it remained elevated above normal values (>330 CU). Most symptoms almost disappeared at 24 hours in the Robuvit® group. Significant symptoms were still observed in 11 out of 19 subjects in the SM group in comparison with four of 22 subjects using the supplementation with Robuvit® (P<0.05). Blood tests were normal in all subjects (hematocrit and kidney and liver functional test at 24 hours).
In conclusion, Robuvit® supplementation appears to improve hangover and relieved symptoms faster. More studies are needed to confirm this association between acute alcohol consumption and a possible hepatic dysfunction.
本开放性注册研究旨在评估 Robuvit® 在急性酒精摄入后出现宿醉的受试者中的作用，同时测量氧化应激水平的变化。比较了使用标准治疗（SM）的一组和使用 SM 并连续 3 天每天使用 300mg Robuvit®的一组。
将 19 名有宿醉症状的男性受试者纳入 SM 组，22 名纳入 Robuvit®+SM 组。
两组在基线时具有可比性。未观察到不良反应。疲劳评分 - 作为这些受试者的主要观察症状，在两组中 - 在 24 小时后使用 Robuvit®的组（P<0.05）明显低于对照组。其他症状（如虚弱、口渴、头痛、肌肉疼痛和身体疼痛）的评分在 24 小时（P<0.05）时也明显低于对照组，且补充剂组的胃肠道残留症状（恶心、呕吐和胃痛）评分也较低（P<0.05）。睡眠和休息在使用 Robuvit®时明显更好（P<0.05）。与仅使用 SM 相比，感官症状和认知功能也得到了显著改善（P<0.05）。最后，使用 Robuvit®时，情绪、注意力、抑郁、焦虑、烦躁等评分明显较低（P<0.05），尽管这些症状需要更具体和完整的评估。在 24 小时时，自主神经活动、震颤、出汗、心率增加等迹象的改善也明显优于补充剂（P<0.05）。所有受试者的氧化应激在纳入时均升高；在 Robuvit®组，氧化应激在 24 小时时显著降低（P<0.05）；在对照组（SM）中，氧化应激在 24 小时时仅表现出最小变化，且仍高于正常值（>330 CU）。在 Robuvit®组中，大多数症状在 24 小时时几乎消失，但在 SM 组的 19 名受试者中仍有 11 名存在明显症状，而使用 Robuvit®补充剂的 22 名受试者中仅有 4 名（P<0.05）。所有受试者的血液检查均正常（24 小时时的血细胞比容和肝肾功能检查）。
总之，Robuvit®补充剂似乎可以更快地改善宿醉并缓解症状。需要更多的研究来证实急性酒精摄入与可能的肝功能障碍之间的这种关联。
